Latest News

The National Advertising Review Board upheld the National Advertising Division’s recommendations that Tru Niagen discontinue use of its “clinically proven” claims. Niagen argued this goes against established precedent from the NAD and Federal Trade Commission.

The FDA investigation, which closed April 1, tied recalled moringa supplements to more than 100 illnesses, drawing renewed industry attention to testing, traceability and supplier verification practices.

The U.S. Food and Drug Administration (FDA) rarely goes after eBay sellers, which is exactly why it caught Asa Waldstein’s eye.

Companies that build proactive regulatory frameworks are scaling faster, earning retailer trust and outpacing competitors that treat compliance as an afterthought.

Mouth pouches have emerged as one of the fastest growing CPG categories, signaling a major trend in nootropics as consumers seek functional ways to boost performance—sans nicotine.

Emerging enforcement trends include FDA focus on documentation and identity testing, and increased scrutiny of online claims

Apex Compliance’s Asa Waldstein shares valuable insights for those seeking to avoid an FDA warning letter, a competitor case with the NAD or a referral to the FTC due to ad claims non-compliance.

The National Advertising Division (NAD) has recommended that Reus Research LLC modify or discontinue several advertising claims related to its Cata-Kor NAD+ Core and Advanced dietary supplements.

Asa Waldstein is our guest on KISC My Health Radio show with Peter Mingils and the King of Cranberries Stephen Lukawski.

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters and other enforcement impacting manufacturers and marketers of dietary supplements.

The case highlights compliance risk for functional beverages and ingredient claims among dietary supplement and food‐adjacent product manufacturers.

The American Herbal Products Association hosted its first botanical congress outside the confines of the SupplySide Global trade show.

Asa and other industry leaders weighed in

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Asa and other industry leaders weigh in

Labeling disputes over protein content and daily values continue to attract legal attention, particularly in California

Asa and other industry leaders weigh in

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Jennifer Adam and Asa Waldstein provide commentary in this article by Cassandra Stern.

Cognition and memory products are big business, and the Food and Drug Administration (FDA), National Advertising Division (NAD), Federal Trade Commission (FTC) and plaintiff attorneys are paying attention.